JNJ Stock Forecast & Price Target

Johnson & Johnson is viewed positively because its post-consumer-separation structure has sharpened focus on innovation, productivity, and margin improvement across Innovative Medicines and MedTech. The fundamental growth case is anchored by strong momentum in Immunology, Oncology, and Neuroscience, with Tremfya, Darzalex, Icotyde, and Spravato supporting higher revenue while pipeline breadth and recent launches point to competitive growth into 2026–30E. Even after a ~6% sell-off and persistent MedTech headwinds, the company’s scale, category-leading platforms, and ability to generate strong free cash flow and return cash to shareholders support its defensive quality.

Johnson & Johnson is viewed negatively because its growth outlook depends on pipeline execution that may disappoint, while loss of exclusivity on products such as Stelara is already eroding revenue and could weigh more heavily in 2H of the decade. MedTech adds another layer of risk, as persistent competitive headwinds in electrophysiology and pulsed field ablation, plus weaker-than-expected uptake of new products, could delay the hoped-for recovery and keep organic growth subdued. At the same time, M&A integration risk, ongoing talc and other litigation, and higher settlement costs threaten P&L discipline and margins, even as 1H erosion of Stelara was about 57% and full-year erosion guidance remains near 60%.